Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast

Presently, pharmacotherapies approved to treat cognitive and functional impairment in AD are limited to a handful of small molecules (e.g.,donepezil, memantine) that provide modest, symptomatic cognitive benefit for a limited duration. For decades, attrition among putative DMTs for AD has stood at 100%, but in June 2021, Biogen / Eisai’s anti-Aβ MAbaducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of AD, rendering it the first potential DMT approved for this disease. Other products in the class may soon follow (Eisai / Biogen’s lecanemab, Eli Lilly’s donanemab, Roche’s gantenerumab). Meanwhile, hope remains for therapies from Lundbeck, Otsuka, Avanir, Acadia, and Axsome that are in late-phase development to treat key neuropsychiatric symptoms. Ultimately, the launch of these potential blockbusters is far from certain, but could return a heavily generic market to enormous growth.

QUESTIONS ANSWERED

  • How large is the treatable AD population? What will be the impact of DMTs (should any launch) on diagnosis / drug treatment rates?
  • What are the KOLs’ opinions of Biogen’s aducanumab and other agents in development (e.g., lecanemab, donanemab, gantenerumab)?
  • What commercial uptake can be expected from Rexulti, AVP-786,and AXS-05 should they launch for AD agitation?
  • What are the drivers and constraints in the AD market, and how might they change over the forecast period as premium-priced agents enter the market?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
    • Key Findings
      • Alzheimer's Disease Key Findings - February 2022
        • June 2021
        • May 2021
    • Market Outlook
      • Key Findings
        • Market Share of Alzheimer's Disease Drug Classes: 2020
        • Market Share of Alzheimer's Disease Drug Classes: 2030
        • Alzheimer's Disease SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Alzheimer's Disease?
        • What Factors Are Constraining the Market for Alzheimer's Disease?
        • Major-Market Sales of Alzheimer's Disease Therapies by Disease Subtype: 2020-2030
        • Major-Market Drug-Treated Alzheimer's Disease Patient Populations: 2020-2030
      • Drug-Class-Specific Trends
        • Major-Market Patient Share of Behavioral Therapies in Alzheimer's Disease: 2020-2030
        • Anti-Au03b2 Monoclonal Antibodies
        • Major-Market Sales and Patient Share of Disease-Modifying Therapies in MCI due to AD: 2020-2030
        • Major-Market Sales and Patient Share of Disease-Modifying Therapies in Mild AD: 2020-2030
        • Major-Market Sales in Alzheimer's Disease, by Therapeutic Group: 2020-2030
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Amyloid Plaques and Neurofibrillary Tangles in Alzheimeru2019s Disease
      • Etiology
        • Genetic Risk Factors for Alzheimer's Disease
        • Genes Associated With Familial Alzheimeru2019s Disease
        • Nongenetic Risk Factors for Alzheimer's Disease
      • Pathophysiology
        • Leading Pathophysiological Hypotheses in Alzheimer's Disease
        • Normal and Pathogenic Cleavage of Amyloid Precursor Protein
      • Disease Progression / Natural History
        • Brain Atrophy in Alzheimeru2019s Disease
      • Key Pathways and Drug Targets
        • Key Drug Targets
        • Key Strategies and Drug Targets in Alzheimer's Disease
    • Epidemiology
      • Key Findings
        • Epidemiology Populations
          • 2020 Model Update
          • Disease Definition
          • Methods
          • Sources Used for Total Prevalent Cases of Asymptomatic Alzheimeru2019s Disease
          • Total Prevalent Cases of Asymptomatic Alzheimeru2019s Disease in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Disease Definition
          • Methods
          • Sources Used for Total MCI due to AD
          • Total Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Disease Definition
          • Methods
          • Sources Used for Total Prevalent Cases of Alzheimeru2019s Disease
          • Total Prevalent Cases of Alzheimer's Disease in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Multistate Model of the Progression of Alzheimer's Disease
          • Disease Definition
          • Methods
          • Sources Used for Total Prevalent Cases of Alzheimer's Disease by Severity
          • Total Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Prevalent Cases of Alzheimer's Disease by Symptom Status
          • Diagnosed Prevalent Cases of Alzheimer's Disease by Symptom Status: 2020-2030 (Thousands)
          • Diagnosed Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Diagnosed Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Drug-Treated Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
          • Drug-Treated Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2020-2030 (Thousands)
      • Current Treatment
        • Key Findings
          • Treatment Goals
            • Key Endpoints Used in Clinical Trials for Alzheimer's Disease
          • Key Current Therapies
            • Overview of Alzheimer's Disease Drug Classification
            • Mechanism of Action of Key Current Drug Classes Used for Alzheimeru2019s Disease
            • Current Treatments Used for Alzheimeru2019s Disease
            • Market Events Impacting the Use of Key Current Therapies in Alzheimer's Disease
            • Advantages and Disadvantages of Donepezil
            • Advantages and Disadvantages of Rivastigmine
            • Advantages and Disadvantages of Galantamine
            • Advantages and Disadvantages of Memantine
            • Advantages and Disadvantages of Antipsychotics
            • Advantages and Disadvantages of Antidepressants
            • Advantages and Disadvantages of Aduhelm
            • Key Results From Select Clinical Trials of Aduhelm for the Treatment of Alzheimer's Disease
            • Ongoing Clinical Development of Aduhelm
            • Expert Insight: Aduhelm
            • Revised Diagnostic Guidelines
            • Summary of Diagnostic Guidelines for Alzheimeru2019s Disease and Subsequent Revisions
            • Diagnostic Biomarkers
            • Non-PET-Imaging-Related Diagnostic Biomarkers
            • PET Imaging
            • Factors Influencing the Use of PET Imaging Biomarkers
          • Medical Practice
            • Overview
            • Factors Influencing Drug Selection in Alzheimeru2019s Disease
            • Region-Specific Treatment Practices
            • Treatment Decision Tree for Alzheimer's Disease: United States
            • Treatment Decision Tree for Alzheimer's Disease: Europe
            • Treatment Decision Tree for Alzheimer's Disease: Japan
        • Unmet Need Overview
          • Current and Future Attainment of Unmet Needs in Alzheimer's Disease
          • Top Unmet Needs in Alzheimer's Disease: Current and Future Attainment
        • Emerging Therapies
          • Key Findings
            • Key Emerging Therapies
              • Key Therapies in Development for Alzheimer's Disease
              • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Alzheimer's Disease
              • Drug Development and Regulatory Hurdles
              • Drug Development and Regulatory Hurdles in Alzheimer's Disease
              • Select Ongoing Clinical Trials of Disease-Modifying Therapies in the Treatment of Alzheimer's Disease
              • Select Ongoing Prevention Trials in Alzheimeru2019s Disease
              • Key Results From Select Clinical Trials Investigating Lecanemab for the Treatment of Alzheimer's Disease
              • Analysis of the Clinical Development Program for Lecanemab
              • Expert Insight: Lecanemab
              • Expectations for Launch and Sales Opportunity of Lecanemab in Alzheimer's Disease
              • Key Results From Select Clinical Trials Investigating Donanemab for the Treatment of Alzheimer's Disease
              • Analysis of the Clinical Development Program for Donanemab
              • Expert Insight: Donanemab
              • Expectations for Launch and Sales Opportunity of Donanemab in Alzheimer's Disease
              • Key Results From Select Clinical Trials Investigating Gantenerumab for the Treatment of Alzheimer's Disease
              • Analysis of the Clinical Development Program for Gantenerumab
              • Expectations for Launch and Sales Opportunity of Gantenerumab in Alzheimer's Disease
              • Analysis of the Clinical Development Program for Semaglutide
              • Expert Insight: Semaglutide
              • Expectations for Launch and Sales Opportunity of Semaglutide in Alzheimer's Disease
              • Rexulti Profile
              • Analysis of the Clinical Development Program of Rexulti
              • Expert Insight: Rexulti
              • Expectations for Launch and Sales Opportunity of Rexulti in Alzheimer's Disease
              • Nuplazid Profile
              • Analysis of the Clinical Development Program for Nuplazid
              • Expert Insight: Nuplazid
              • Expectations for Launch and Sales Opportunity of Nuplazid in Alzheimer's Disease
              • AVP-786 Profile
              • Analysis of the Clinical Development Program for AVP-786
              • Expert Insight: AVP-786
              • Expectations for Launch and Sales Opportunity of AVP-786 in Alzheimer's Disease
              • AXS-05 Profile
              • Analysis of the Clinical Development Program of AXS-05
              • Expert Insight: AXS-05
              • Expectations for Launch and Sales Opportunity of AXS-05 in Alzheimer's Disease
              • Adlarity Profile
              • Analysis of Clinical Development Program for Adlarity
              • Expert Insight: Adlarity
              • Expectations for Launch and Sales Opportunity of Adlarity in Alzheimer's Disease
              • BXCL-501 Profile
              • Analysis of the Clinical Development Program for BXCL-501
              • Expert Insight: BXCL-501
              • Expectations for Launch and Sales Opportunity of BXCL-501 in Alzheimer's Disease
              • Recent Late-Phase DMT Failures in AD
            • Early-Phase Pipeline Analysis
              • Select Disease-Modifying Compounds in Phase II Development for Alzheimer's Disease
              • Select Symptomatic Compounds in Phase II Development for Alzheimer's Disease
          • Access & Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market-Access Considerations in Alzheimer's Disease: United States
              • General Reimbursement Environment: United States
              • Key Market-Access Considerations in Alzheimer's Disease: EU5
              • General Reimbursement Environment: EU5
              • Key Market-Access Considerations in Alzheimer's Disease: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Alzheimer's Disease Bibliography